Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Lilly Broadens Its Alzheimer’s R&D
by Michael McCoy
April 22, 2013
| A version of this story appeared in
Volume 91, Issue 16
Eli Lilly & Co. has acquired two investigational positron emission tomography tracers from Siemens Medical Solutions as part of its effort to develop treatments for Alzheimer’s disease. The tracers image tau tangles in the brain, one of two known hallmarks of the disease along with amyloid-β plaques. Lilly had been developing the antibody solanezumab to block the formation of amyloid-β, but the drug failed in clinical trials last year. The firm now says it has established R&D programs to explore both amyloid-β and tau.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter